Key Findings From Recent Trials

Basic Cyclogest Information

• INN (International Nonproprietary Name): Progesterone
• Brand Names Available In United Kingdom: Utrogestan
• ATC Code: G03DA04
• Forms & Dosages: Soft capsules 100 mg, 200 mg (blister packs 30/90); vaginal capsules/softgels 100 mg, 200 mg (boxes 15/30); compounding powders (rare, variable)
• Manufacturers In United Kingdom: Besins Healthcare; AbbVie; Teva; Mylan
• Registration Status In United Kingdom: Registered under brand names such as Utrogestan; prescription-only (Rx)
• OTC / Rx Classification: Prescription only (Rx)

Major 2022–2025 Studies

Clinicians and researchers focused on micronised progesterone for two primary areas: luteal support in assisted reproduction and endometrial protection with HRT.

Randomised trials and large observational cohorts published between 2022 and 2025 compared vaginal and oral routes for luteal-phase support.

Other studies contrasted natural micronised progesterone against synthetic progestins for longer-term HRT safety signals.

Key brands appearing in reports include Utrogestan and Prometrium as the representative micronised progesterone preparations.

Many papers emphasised real‑world practice around vaginal use of oral capsules for fertility, noting widespread off‑label adoption.

Comparative safety datasets suggested different cardiovascular and breast safety profiles between micronised progesterone and some synthetic progestogens.

Study sizes ranged from randomised trials to large registry and observational analyses across Europe and North America.

Main Outcomes

When vaginal micronised progesterone was used for luteal support, pregnancy outcomes were generally similar to comparator regimens in randomised trials.

Trials reported fewer systemic sedative complaints with vaginal administration versus oral bedtime dosing in several cohorts.

For HRT, micronised progesterone alongside oestrogen provided endometrial protection and showed favourable signals in observational breast and cardiovascular assessments.

Overall efficacy for endometrial protection and induction of withdrawal bleeding in amenorrhoea is consistent with historical product data.

Safety Observations

Most trials recorded predictable adverse events such as headache, breast tenderness and fatigue.

Rare signals included sedation with oral bedtime dosing and cautionary notes for severe hepatic dysfunction or prior thrombosis.

Regulatory approvals and labelling differ by jurisdiction, and product names most referenced are Utrogestan (EU/UK) and Prometrium (US/Canada).

Clinical Mechanism Of Action

Layman’s Explanation

People often ask how progesterone actually helps the womb and pregnancy.

Progesterone is the body's natural progestogen that prepares the lining of the uterus for implantation and supports early pregnancy.

In HRT it balances oestrogen to prevent excessive lining growth and reduce bleeding risk.

Micronised formulations improve the way oral capsules dissolve and are absorbed compared with crude powders.

This change in formulation can alter the balance between local endometrial effect and systemic side effects like sleepiness.

Scientific Breakdown

Progesterone acts primarily via nuclear progesterone receptors to change gene transcription in endometrial stromal and epithelial cells.

These genomic actions promote secretory transformation and suppress proliferative responses driven by oestrogen.

Non‑genomic, membrane receptor-mediated actions contribute to neurosteroid effects and can explain somnolence and mood changes with systemic absorption.

Micronised, natural progesterone differs from synthetic progestins in receptor interactions and systemic metabolic consequences.

Pharmacokinetics & Micronisation

Micronisation reduces particle size and increases dissolution in the gastrointestinal tract for oral softgels (100 mg, 200 mg).

Oral micronised progesterone undergoes significant first‑pass hepatic metabolism, which affects systemic exposure.

Vaginal administration bypasses first‑pass metabolism and yields higher local endometrial concentrations with lower systemic levels.

That pharmacokinetic difference often accounts for reduced daytime sedation when vaginal regimens are used for luteal support.

Scope Of Approved And Off-Label Use

United Kingdom Approvals

National product information and the EMA/UK registries list micronised progesterone under brand names such as Utrogestan.

In the UK it is supplied as prescription-only soft capsules, typically 100 mg and 200 mg strengths in blister packs.

Licensed indications include endometrial protection during combined HRT and other gynaecological uses referenced in SPCs.

Regulatory labelling in the EU commonly uses the term “micronised” on packaging.

Notable Off-Label Trends

One of the most widespread off‑label practices is vaginal administration of oral capsules for luteal support in IVF clinics and private practice.

Clinicians also report using micronised progesterone in threatened miscarriage, although evidence is mixed and guidance varies.

Vaginal use is commonly referenced in clinical practice across parts of Europe and Asia despite variable labelling.

When counselling, check the product leaflet for excipients such as peanut oil and follow local protocols for off‑label use.

Dosage Strategy

General Dosing

Dosing depends on indication, route of administration and individual patient factors including hepatic function.

For endometrial protection in HRT, product literature commonly recommends 200 mg orally once daily at bedtime for 12 days of a 28‑day cycle.

For secondary amenorrhoea the standard is 400 mg orally at bedtime once daily for 10 days, per product information.

Soft capsules are available as 100 mg and 200 mg strengths in blister packs of 30 or 90 units, while vaginal packs come in 15 or 30 packs.

Condition-Specific Dosing

In assisted reproduction, luteal support regimens commonly use 100–200 mg vaginally once or twice daily, with local practice variation.

Clinicians often individualise dose and route to reduce systemic sedation, switching to vaginal route when needed.

Always review renal and hepatic status before long‑term dosing and adjust where product literature advises caution.

Safety Protocols

Contraindications

Certain conditions make micronised progesterone unsuitable and these are listed as absolute contraindications in product data.

Absolute contraindications include severe liver dysfunction, known or suspected hormone‑dependent malignancy, undiagnosed vaginal bleeding and current or prior thrombotic disease.

Peanut allergy is an absolute contraindication for formulations that contain peanut oil; check packaging for allergen labelling.

Use caution or avoid use in pregnancy for indications where the product is not intended, as per SPCs.

Adverse Effects

Common adverse effects include headache, breast tenderness, abdominal cramps, dizziness, fatigue and mood changes.

Oral bedtime dosing can cause systemic sedation in some patients and should prompt consideration of the vaginal route if problematic.

Overdose typically produces nausea, vomiting, sedation and withdrawal bleeding; supportive care is standard.

Monitor patients with migraine, depression, asthma or cardiovascular disease more closely as relative contraindications exist.

Interaction Mapping

Food Interactions

There are no routine food interactions listed that lower efficacy, but alcohol can increase sedation when combined with oral dosing.

Advise patients to avoid heavy alcohol intake around the time of bedtime dosing to reduce drowsiness risk.

Taking oral softgels with food may affect absorption modestly; follow product instructions and local guidance.

Drug Combinations To Avoid

Progesterone is metabolised hepatically and strong CYP3A4 inducers such as rifampicin, carbamazepine and phenytoin may lower plasma concentrations.

Concomitant oestrogen is routine in HRT but requires assessment of venous thromboembolism risk before combined therapy.

Interactions with anticoagulants or anticonvulsants need specialist review and pharmacy verification against UK formularies.

Co-prescribed sedatives or CNS depressants may potentiate drowsiness with oral micronised progesterone.

Patient Experience Analysis

Survey Data

Patients consistently report that route of administration affects tolerability and adherence.

Vaginal use tends to reduce systemic sedation and daytime sleepiness compared with oral bedtime dosing.

However, vaginal regimens are associated with local discharge and practical inconveniences that can affect adherence.

UK patients on HRT sometimes say nightly dosing improves sleep but also report residual daytime fatigue in some cases.

Forum Trends

Online forums commonly discuss off‑label vaginal use of Utrogestan oral capsules and practical tips for administration.

Patients also raise concerns about peanut oil excipients in certain capsule formulations and seek allergen-free options.

Clinicians should validate anecdotal reports and counsel patients using evidence and product information rather than forum advice alone.

Distribution And Pricing Landscape

The global market for micronised progesterone is led by Besins Healthcare and AbbVie with multiple generics available from Teva, Mylan and others.

Packaging formats include blister packs of 30 or 90 soft capsules and vaginal packs of 15 or 30 units depending on market.

In the UK, Utrogestan is the commonly referenced brand and micronised progesterone is supplied as prescription-only via NHS and private pharmacies.

Generic competition in the UK helps moderate costs for soft capsules and vaginal preparations.

Increased demand for vaginal formulations in fertility care has driven repackaging practices in some regions, which pharmacies must follow with documented stability data.

For patients wanting a private option, our online pharmacy lists cyclogest available without a prescription with discreet delivery to United Kingdom in 5-14 days.

Alternative Options

Comparison Table

There are several alternatives to micronised progesterone depending on desired route and safety profile.

Medroxyprogesterone (Provera) is a synthetic progestin available as tablets and injectables with established dosing options.

Dydrogesterone (Duphaston) is an oral synthetic progestogen that tends to cause less sedation than natural progesterone.

Other micronised progesterone generics offer the same active ingredient with different excipients that may affect tolerability.

Pros And Cons

Micronised progesterone advantages include its natural profile and possibly more favourable breast and VTE signals versus some synthetics in observational studies.

Disadvantages include oral sedation and the presence of peanut oil in some capsule formulations.

Medroxyprogesterone advantages are convenient dosing and broad availability, while disadvantages include different metabolic and cardiovascular signal profiles.

Choice should be individualised, considering VTE risk, route preference and licensing in the UK.

Regulatory Status

Progesterone is classified under ATC code G03DA04 and marketed globally under various brands such as Utrogestan and Prometrium.

The FDA in the US has specific approvals for secondary amenorrhoea and endometrial protection with oestrogen.

EMA and UK registries list micronised progesterone products across member states with varying labelling terminology, often including “micronised” or “micronisée.”

In Romania the product appears in national registries such as ANMDMR under Utrogestan and Prometrium.

Across jurisdictions the product is generally prescription-only (Rx), and clinicians should consult current SPCs and MHRA guidance for the UK.

Consolidated FAQ

Rapid Clinician Answers

Q: Can oral Utrogestan be used vaginally?

A: Off‑label vaginal use of oral micronised capsules is common for luteal support; follow local protocols and counsel patients accordingly.

Q: Is it safe in patients with peanut allergy?

A: Some capsules contain peanut oil; check the product leaflet and avoid those formulations if allergic.

Q: What dose for endometrial protection?

A: Product information commonly recommends 200 mg orally at bedtime for 12 days of a 28‑day cycle.

Q: What about liver impairment?

A: Contraindicated in severe hepatic dysfunction; use caution in moderate impairment and monitor closely.

Q: Missed dose?

A: Take as soon as remembered unless it is near the next dose; do not double up.

Visual Guide

Suggested Diagrams And Captions

Diagram 1: Route Comparison — show oral micronised versus vaginal delivery with relative systemic versus local concentrations.

Caption: Vaginal administration produces higher endometrial exposure and lower systemic sedation compared with oral dosing.

Diagram 2: Dosing Flowchart — map indication to route choice and standard dose (e.g., 400 mg amenorrhoea; 200 mg HRT; 100–200 mg vaginal IVF).

Caption: Use licensed doses where indicated and individualise based on tolerability and hepatic function.

Diagram 3: Safety Checklist — icons for contraindications, peanut allergy flag and hepatic warning.

Caption: Check SPCs for up‑to‑date contraindications and allergen information; INN “progesterone”, ATC G03DA04, prescription only in the UK.

Capsule Imagery: include labelled photos of 100 mg and 200 mg softgels and typical blister packs to aid identification of Utrogestan and Prometrium branding.

Storage And Transport

Store micronised progesterone soft capsules below 25°C and protect from moisture and light as stated in product monographs.

Keep medication in original packaging and do not refrigerate or freeze.

Blister packs and vaginal formats should remain sealed until use to maintain stability.

For pharmacies and clinics, avoid prolonged exposure to heat during transit and document temperature control for repackaged items.

US packaging includes peanut allergen warnings; store allergen‑containing items separately if required in clinic dispensing.

Instruct patients to discard expired units via local waste disposal guidance and to keep medicines away from children.

Guidelines For Proper Use

Prescriber Checklist

Confirm the indication and review the patient’s VTE and breast cancer risk before prescribing micronised progesterone.

Check hepatic function and screen for peanut allergy, then document the chosen route and clinical rationale.

Use licensed doses: for secondary amenorrhoea 400 mg orally nightly for 10 days; for HRT 200 mg nightly for 12 days per 28‑day cycle.

Monitor elderly patients for increased sensitivity and avoid in severe hepatic dysfunction.

Patient Counselling Points

Explain benefits such as endometrial protection or luteal support and outline common side effects like drowsiness, breast tenderness and mood changes.

Advise storage below 25°C and missed‑dose actions: take as soon as remembered unless close to the next dose; do not double up.

Tell patients to seek immediate help for symptoms of thrombosis, severe liver problems or signs of allergic reaction.

Direct patients to NHS guidance and the product SPC for brand‑specific allergen and safety information.

Delivery Across United Kingdom